Teclistamab-cqyv (Tecvayli) — CPB 1018 | AETNA Coverage Update

TL;DR: Aetna modified CPB 1018 covering teclistamab-cqyv (Tecvayli) for relapsed or refractory multiple myeloma, effective October 19, 2025. Here's what changes for billing teams.

The updated Aetna teclistamab-cqyv coverage policy now includes a second approval pathway: combination use with talquetamab-tgvs (Talvey) after just three prior therapies. That's a meaningful expansion from the original single-agent criteria, which required at least four prior therapies. If your team bills J9380 for Tecvayli or J3055 for talquetamab-tgvs, this policy shift opens reimbursement for a broader patient population — but the prior authorization requirements remain strict, and the documentation burden is real.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Teclistamab-cqyv (Tecvayli) — CPB 1018
Policy Code	CPB 1018
Change Type	Modified
Effective Date	October 19, 2025
Impact Level	High
Specialties Affected	Oncology, Hematology, Specialty Pharmacy, Infusion Centers
Key Action	Update prior authorization workflows to document the new combination pathway with talquetamab-tgvs and verify therapy-line counts before submitting claims under J9380 or J3055

---

Aetna Teclistamab-cqyv Coverage Criteria and Medical Necessity Requirements 2025

Teclistamab-cqyv billing under CPB 1018 Aetna hinges on meeting one of two distinct pathways. Getting this wrong at the authorization stage means claim denial — and for a drug at this price point, that's not a recoverable mistake.

Pathway 1 — Single Agent (J9380 only):
The member must have relapsed or refractory multiple myeloma and have received at least four prior therapies. Those therapies must span all three of the following drug classes:

#	Covered Indication Copy
1	A proteasome inhibitor — bortezomib (J9041, J9044), ixazomib, or carfilzomib (J9047)
2	An immunomodulatory agent — lenalidomide, pomalidomide, or thalidomide
3	An anti-CD38 monoclonal antibody — daratumumab (J9145) or isatuximab (J9227)

All three classes must be represented. Not two out of three — all three. If a patient received four therapies but never got an anti-CD38 agent, Aetna will not approve Tecvayli under this pathway.

Pathway 2 — Combination with Talquetamab-tgvs (J9380 + J3055):
This is the new pathway added in the October 19, 2025 update. The member still needs relapsed or refractory multiple myeloma, but the prior therapy requirement drops to three. There's no listed requirement to have hit all three drug classes.

This matters because some patients exhaust options faster. If a member has had three lines of therapy and is a candidate for bispecific combination treatment, Tecvayli may now be covered before the four-line threshold. That's a real clinical and financial win — but only if your authorization documentation is clean.

Prior authorization is required for every patient on every plan design. Call (866) 752-7021 or fax the SMN form to (888) 267-3277. There are no exceptions for self-administered dosing or specialty pharmacy billing — the precertification requirement applies regardless of site of care.

Continuation of therapy requires reauthorization. Aetna covers ongoing Tecvayli when there's no evidence of unacceptable toxicity or disease progression on the current regimen. Your clinical team needs to document stable or responding disease at each reauthorization cycle.

This coverage policy applies to commercial medical plans only. Medicare patients fall under a separate pathway — check Aetna's Medicare Part B criteria directly, as CPB 1018 does not govern those members.

---

Aetna Teclistamab-cqyv Exclusions and Non-Covered Indications

Aetna's position is clear: any use of Tecvayli outside the two pathways above is experimental, investigational, or unproven.

That means Tecvayli as monotherapy for a patient with fewer than four prior lines — without the talquetamab combination — will be denied. Use as first-line, second-line, or third-line single-agent therapy is not covered. Any indication outside relapsed or refractory multiple myeloma (C90.0, C90.1, C90.2) gets the same answer.

There's no smudge room here. Aetna wrote the exclusion broadly and didn't carve out any emerging indications or clinical trial language that might soften a peer-to-peer. If a provider wants to argue medical necessity for an off-label use, they're starting from a very hard "no."

---

Coverage Indications at a Glance

---

Aetna Teclistamab-cqyv Billing Guidelines and Action Items 2025

The effective date of October 19, 2025 has already passed. If you're billing Tecvayli under CPB 1018 and haven't updated your workflows, you're behind.

Copy Action Items

If your payer mix includes a high volume of relapsed/refractory myeloma patients, the shift in reimbursement eligibility for combination therapy is worth a formal review with your compliance officer before submitting under the new pathway.

---

CPT, HCPCS, and ICD-10 Codes for Teclistamab-cqyv (Tecvayli) Under CPB 1018

HCPCS Codes — Covered When Selection Criteria Are Met

Note: J9041, J9044, J9047, J9145, and J9227 appear in CPB 1018 to document prior therapy class exposure — they're referenced as qualifying prior treatments, not necessarily billed on the same claim as J9380.

CPT Codes — Infusion Administration

Key ICD-10-CM Diagnosis Codes

Code	Description Copy
C90.0	Multiple myeloma
C90.1	Multiple myeloma
C90.2	Multiple myeloma

Confirm your EHR maps the correct C90 subcode for each patient's disease status. Aetna's criteria center on relapsed or refractory disease, and your diagnosis code needs to support that clinical picture in the record.

---